O	0	10	Prevention
O	11	13	of
B-condition	14	27	pegfilgrastim
I-condition	27	28	-
I-condition	28	35	induced
I-condition	36	40	bone
I-condition	41	45	pain
O	45	46	:
O	47	48	a
O	49	54	phase
O	55	58	III
O	59	65	double
O	65	66	-
O	66	71	blind
O	72	79	placebo
O	79	80	-
O	80	90	controlled
O	91	101	randomized
O	102	110	clinical
O	111	116	trial
O	117	119	of
O	120	123	the
O	124	134	university
O	135	137	of
O	138	147	rochester
O	148	154	cancer
O	155	161	center
O	162	170	clinical
O	171	180	community
O	181	189	oncology
O	190	197	program
O	198	206	research
O	207	211	base
O	211	212	.

O	213	226	Pegfilgrastim
O	226	227	-
O	227	234	induced
O	235	239	bone
O	240	244	pain
O	245	247	is
O	248	249	a
O	250	261	significant
O	262	270	clinical
O	271	278	problem
O	279	283	that
O	284	287	may
O	288	294	result
O	295	297	in
O	298	313	discontinuation
O	314	316	of
O	317	330	pegfilgrastim
O	331	334	and
O	335	339	lead
O	340	342	to
O	343	347	less
O	348	357	effective
O	358	370	chemotherapy
O	371	377	dosing
O	377	378	.

O	379	392	Interventions
O	393	396	for
O	397	410	pegfilgrastim
O	410	411	-
O	411	418	induced
O	419	423	bone
O	424	428	pain
O	429	432	are
O	433	439	needed
O	439	440	.

O	441	444	The
O	445	455	University
O	456	458	of
O	459	468	Rochester
O	469	475	Cancer
O	476	482	Center
O	483	491	Clinical
O	492	501	Community
O	502	510	Oncology
O	511	518	Program
O	519	527	Research
O	528	532	Base
O	533	541	randomly
O	542	550	assigned
B-total-participants	551	554	510
O	555	563	patients
O	564	566	at
O	567	569	17
O	570	575	sites
O	576	578	to
O	579	586	receive
O	587	593	either
B-intervention	594	602	naproxen
O	603	604	(
O	604	607	500
O	608	610	mg
O	611	614	two
O	615	620	times
O	621	624	per
O	625	628	day
O	628	629	)
O	630	632	or
B-control	633	640	placebo
O	641	643	on
O	644	647	the
O	648	651	day
O	652	654	of
O	655	668	pegfilgrastim
O	669	683	administration
O	683	684	,
O	685	695	continuing
O	696	699	for
O	700	701	5
O	702	704	to
O	705	706	8
O	707	711	days
O	712	717	after
O	718	731	pegfilgrastim
O	731	732	.

O	733	741	Patients
O	742	750	recorded
O	751	755	pain
O	756	764	severity
O	765	766	(
O	766	771	using
O	772	773	a
O	774	779	scale
O	780	782	of
O	783	784	0
O	785	787	to
O	788	790	10
O	790	791	)
O	792	795	and
O	796	804	duration
O	805	807	in
O	808	813	daily
O	814	821	diaries
O	821	822	.

O	823	826	The
O	827	834	primary
O	835	842	outcome
O	843	850	measure
O	851	854	was
O	855	858	the
B-outcome-Measure	859	863	area
I-outcome-Measure	864	869	under
I-outcome-Measure	870	873	the
I-outcome-Measure	874	879	curve
I-outcome-Measure	880	881	(
I-outcome-Measure	881	884	AUC
I-outcome-Measure	884	885	)
I-outcome-Measure	886	889	for
I-outcome-Measure	890	894	pain
I-outcome-Measure	895	898	for
I-outcome-Measure	899	903	days
I-outcome-Measure	904	905	1
I-outcome-Measure	906	913	through
I-outcome-Measure	914	915	5
O	915	916	.

O	917	926	Secondary
O	927	934	outcome
O	935	943	measures
O	944	952	included
O	953	956	the
O	957	971	identification
O	972	974	of
B-outcome-Measure	975	979	risk
I-outcome-Measure	980	987	factors
I-outcome-Measure	988	991	for
I-outcome-Measure	992	995	the
I-outcome-Measure	996	1007	development
I-outcome-Measure	1008	1010	of
I-outcome-Measure	1011	1015	pain
O	1016	1019	and
B-outcome-Measure	1020	1028	response
I-outcome-Measure	1029	1031	to
I-outcome-Measure	1032	1040	naproxen
O	1040	1041	.

O	1042	1050	Patients
O	1050	1051	'
O	1052	1056	mean
O	1057	1060	age
O	1061	1064	was
B-age	1065	1067	55
I-age	1067	1068	.
I-age	1068	1069	6
I-age	1070	1075	years
O	1076	1079	and
O	1080	1082	86
O	1082	1083	%
O	1084	1088	were
O	1089	1095	female
O	1095	1096	.

O	1097	1102	Sixty
O	1102	1103	-
O	1103	1108	eight
O	1109	1116	percent
O	1117	1119	of
O	1120	1128	patients
O	1129	1132	had
O	1133	1139	breast
O	1140	1146	cancer
O	1147	1150	and
O	1151	1153	10
O	1153	1154	%
O	1155	1158	had
O	1159	1163	lung
O	1164	1170	cancer
O	1170	1171	.

B-outcome	1172	1176	Pain
O	1177	1184	reached
O	1185	1188	its
O	1189	1193	peak
O	1194	1196	at
O	1197	1198	3
O	1199	1203	days
O	1204	1207	for
O	1208	1212	both
O	1213	1219	groups
O	1219	1220	.

O	1221	1224	The
B-outcome	1225	1229	mean
I-outcome	1230	1233	AUC
I-outcome	1234	1237	for
I-outcome	1238	1242	pain
O	1243	1246	was
B-cv-cont-mean	1247	1248	7
I-cv-cont-mean	1248	1249	.
I-cv-cont-mean	1249	1251	71
O	1252	1255	for
O	1256	1259	the
O	1260	1267	placebo
O	1268	1273	group
O	1274	1277	and
B-iv-cont-mean	1278	1279	6
I-iv-cont-mean	1279	1280	.
I-iv-cont-mean	1280	1282	04
O	1283	1286	for
O	1287	1290	the
O	1291	1299	naproxen
O	1300	1305	group
O	1306	1307	(
O	1307	1308	P
O	1309	1310	=
O	1311	1312	.
O	1312	1315	037
O	1315	1316	)
O	1316	1317	.

O	1318	1326	Naproxen
O	1327	1334	reduced
B-outcome	1335	1342	maximum
I-outcome	1343	1347	pain
O	1348	1352	from
B-iv-cont-mean	1353	1354	3
I-iv-cont-mean	1354	1355	.
I-iv-cont-mean	1355	1357	40
O	1358	1360	to
B-iv-cont-mean	1361	1362	2
I-iv-cont-mean	1362	1363	.
I-iv-cont-mean	1363	1365	59
O	1366	1367	(
O	1367	1368	P
O	1369	1370	=
O	1371	1372	.
O	1372	1375	005
O	1375	1376	)
O	1376	1377	.

O	1378	1386	Naproxen
O	1387	1391	also
O	1392	1399	reduced
B-outcome	1400	1407	overall
I-outcome	1408	1412	pain
I-outcome	1413	1422	incidence
O	1423	1427	from
B-iv-cont-mean	1428	1430	71
I-iv-cont-mean	1430	1431	.
I-iv-cont-mean	1431	1432	3
I-iv-cont-mean	1432	1433	%
O	1434	1436	to
B-iv-cont-mean	1437	1439	61
I-iv-cont-mean	1439	1440	.
I-iv-cont-mean	1440	1441	1
I-iv-cont-mean	1441	1442	%
O	1443	1444	(
O	1444	1445	P
O	1446	1447	=
O	1448	1449	.
O	1449	1452	020
O	1452	1453	)
O	1454	1457	and
B-outcome	1458	1466	duration
O	1467	1471	from
B-iv-cont-mean	1472	1473	2
I-iv-cont-mean	1473	1474	.
I-iv-cont-mean	1474	1476	40
O	1477	1479	to
B-iv-cont-mean	1480	1481	1
I-iv-cont-mean	1481	1482	.
I-iv-cont-mean	1482	1484	92
I-iv-cont-mean	1485	1489	days
O	1490	1491	(
O	1491	1492	P
O	1493	1494	=
O	1495	1496	.
O	1496	1499	009
O	1499	1500	)
O	1500	1501	.

O	1502	1505	The
B-outcome	1506	1515	reduction
I-outcome	1516	1518	in
I-outcome	1519	1525	severe
I-outcome	1526	1530	pain
O	1531	1532	(
O	1532	1533	>
O	1534	1535	5
O	1536	1538	on
O	1539	1540	a
O	1541	1546	scale
O	1547	1549	of
O	1550	1551	1
O	1552	1554	to
O	1555	1557	10
O	1557	1558	)
O	1559	1563	from
B-iv-cont-mean	1564	1566	27
I-iv-cont-mean	1566	1567	.
I-iv-cont-mean	1567	1568	0
I-iv-cont-mean	1568	1569	%
O	1570	1572	to
B-iv-cont-mean	1573	1575	19
I-iv-cont-mean	1575	1576	.
I-iv-cont-mean	1576	1577	2
I-iv-cont-mean	1577	1578	%
O	1579	1582	was
O	1583	1587	also
O	1588	1599	significant
O	1600	1601	(
O	1601	1602	P
O	1603	1604	=
O	1605	1606	.
O	1606	1609	048
O	1609	1610	)
O	1610	1611	.

O	1612	1616	Risk
O	1617	1624	factors
O	1625	1630	could
O	1631	1634	not
O	1635	1637	be
O	1638	1648	identified
O	1649	1651	to
O	1652	1659	predict
O	1660	1669	incidence
O	1669	1670	,
O	1671	1679	severity
O	1679	1680	,
O	1681	1683	or
O	1684	1691	ability
O	1692	1694	to
O	1695	1702	prevent
O	1703	1716	pegfilgrastim
O	1716	1717	-
O	1717	1724	induced
O	1725	1729	bone
O	1730	1734	pain
O	1734	1735	.

O	1736	1739	Our
O	1740	1745	phase
O	1746	1749	III
O	1750	1760	randomized
O	1761	1768	placebo
O	1768	1769	-
O	1769	1779	controlled
O	1780	1788	clinical
O	1789	1794	trial
O	1795	1807	demonstrated
O	1808	1812	that
O	1813	1821	naproxen
O	1822	1824	at
O	1825	1826	a
O	1827	1831	dose
O	1832	1834	of
O	1835	1838	500
O	1839	1841	mg
O	1842	1847	twice
O	1848	1851	per
O	1852	1855	day
O	1856	1858	is
O	1859	1868	effective
O	1869	1871	in
O	1872	1880	reducing
O	1881	1884	the
O	1885	1894	incidence
O	1895	1898	and
O	1899	1907	severity
O	1908	1910	of
O	1911	1924	pegfilgrastim
O	1924	1925	-
O	1925	1932	induced
O	1933	1937	bone
O	1938	1942	pain
O	1942	1943	.
